174 related articles for article (PubMed ID: 15300614)
1. Incorrect cost of infliximab in fistulizing Crohn's disease.
Lichtenstein GR
Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614
[No Abstract] [Full Text] [Related]
2. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
3. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
Koelewijn C; Schrijvers A; Oldenburg B
Neth J Med; 2006; 64(7):212-8. PubMed ID: 16929082
[No Abstract] [Full Text] [Related]
4. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
5. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
Chanchlani N; Russell RK
Aliment Pharmacol Ther; 2024 Jul; 60(1):93-94. PubMed ID: 38773786
[No Abstract] [Full Text] [Related]
7. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
[TBL] [Abstract][Full Text] [Related]
8. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
9. Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence.
Feagan BG; Kozma CM; Slaton TL; Olson WH; Wan GJ
J Med Econ; 2014 Dec; 17(12):872-80. PubMed ID: 25162777
[TBL] [Abstract][Full Text] [Related]
10. How costly is non-adherence to infliximab in patients with Crohn's disease?
Selinger CP
J Med Econ; 2014 Dec; 17(12):881-2. PubMed ID: 25243913
[No Abstract] [Full Text] [Related]
11. Cytokine-target therapies cost effective in Crohn's disease?
McClellan K
Drugs R D; 1999 Mar; 1(3):273-4. PubMed ID: 10566045
[No Abstract] [Full Text] [Related]
12. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
13. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
[TBL] [Abstract][Full Text] [Related]
14. Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint.
Hilsden R
Can J Gastroenterol; 2002 Dec; 16(12):865-8. PubMed ID: 12522477
[TBL] [Abstract][Full Text] [Related]
15. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease.
Mitton CR;
Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479
[TBL] [Abstract][Full Text] [Related]
16. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease.
Lindsay JO; Chipperfield R; Giles A; Wheeler C; Orchard T;
Aliment Pharmacol Ther; 2013 Jul; 38(1):52-61. PubMed ID: 23701393
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
Clark W; Raftery J; Song F; Barton P; Cummins C; Fry-Smith A; Burls A
Health Technol Assess; 2003; 7(3):1-67. PubMed ID: 12709295
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
[TBL] [Abstract][Full Text] [Related]
20. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
